SPIDR: small-molecule peptide-influenced drug repurposing

BACKGROUND: Conventional de novo drug design is costly and time consuming, making it accessible to only the best resourced research organizations. An emergent approach to new drug development is drug repurposing, in which compounds that have already gone through some level of clinical testing are ex...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Matthew D., Long, Thomas, Pfalmer, Daniel L., Andersen, Timothy L., McDougal, Owen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902895/
https://www.ncbi.nlm.nih.gov/pubmed/29661129
http://dx.doi.org/10.1186/s12859-018-2153-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902895/
https://www.ncbi.nlm.nih.gov/pubmed/29661129
http://dx.doi.org/10.1186/s12859-018-2153-y

Ejemplares similares